Shares in French drugmaker Sanofi-Aventis (SASY.PA), which is trying to buy U.S. biotech group Genzyme (GENZ.O), fell 5 percent on Friday after a setback to a cancer drug seen worth some $800 million as of 2015. Iniparib, or BSI-201, an experimental drug being developed by Sanofi for a type of advanced breast cancer, failed to extend life or slow disease progression in a late-stage clinical trial, the company said late on Thursday. [ID:nN27281041] The news follows a blow earlier this month for Sanofi's Multaq, its most significant recent launch, after two patients suffered liver failure after taking the heart drug, though Sanofi said no causal link had been established. [ID:nLDE70D17V]
Source
